Alcon and RxSight, an ophthalmic medical device company, have announced a non-exclusive collaboration to jointly develop adjustable presbyopia-correcting intraocular lenses (PCIOLs).
Under the collaboration, the companies will innovate on their respective platforms – RxSight’s post-operative light-adjustable technology and Alcon’s PCIOL optical designs – and then combine them to create a co-developed technology that enables surgeons to fine-tune visual outcomes, after surgery, for their cataract patients who choose a PCIOL.
“Our leading PCIOLs have helped millions of patients reduce or eliminate the need for glasses after cataract surgery,” said David Endicott, Chief Executive Officer of Alcon. “Together with RxSight’s technology, we have the opportunity to develop tunable PCIOLs, giving surgeons even greater confidence to refine outcomes after surgery.”
“We are excited to work with Alcon to provide patients greater access to outcomes customised to their needs after surgery,” said Ron Kurtz, President and Chief Executive Officer of RxSight. “This collaboration underscores our belief in the importance of adjustability and will help accelerate its expansion across a wider base of patients.”
Together with RxSight’s technology, we have the opportunity to develop tunable PCIOLs, giving surgeons even greater confidence to refine outcomes after surgery
As part of the agreement, RxSight will receive a US$60 million upfront payment to begin development. RxSight could receive up to an additional $140 million in payments as development and regulatory milestones are met. Additionally, under the agreement, Alcon will lead global commercialisation, while RxSight will be responsible for development and manufacturing and receive royalties on net sales.
